CD274 and urinary bladder cancer: PD-L1 is highly palmitoylated in cisplatin-resistant bladder cancer cells, inhibition of fatty acid synthase (FASN) suppresses PD-L1 expression and palmitoylation, suggesting that the FASN-PD-L1 targeting therapy may be used for bladder cancer patients [300].